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Background: VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for
non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced
NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of
carboplatin or cisplatin with pemetrexed.
Methods: The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline. The primary
end point was progression-free survival (PFS); secondary end points included overall survival (OS) and objective response.
Exploratory analyses of end points separately in carboplatin/pemetrexed and cisplatin/pemetrexed subgroups were also
conducted.
Results: Patients classified as VeriStrat Good had longer PFS and OS than VeriStrat Poor: 6.5 vs 1.6 months and 10.8 vs 3.4 months,
respectively; the corresponding hazard ratios (HRs) were 0.36 (Po0.0001) and 0.26 (Po0.0001); they were also more likely to
achieve objective response. Prognostic significance of VeriStrat was confirmed in multivariate analysis. Significant differences in
OS and PFS between Veristrat classifications were also found when treatment subgroups were analysed separately.
Conclusions: The trial demonstrated clinical utility of VeriStrat as a prognostic test for standard first-line chemotherapy of non-
squamous advanced NSCLC.
Non-small cell lung cancer (NSCLC) is one of the major causes of
cancer-related death worldwide. The 5-year survival rate depends
markedly on stage at diagnosis, from 49 to 16 to 2% for patients
with local, regional, and distant-stage disease, respectively (Ries
et al, 2005). There is no cure for patients with stage IV NSCLC, and
the therapeutic goal for such patients is the prolongation of
survival while alleviating symptoms and improving quality of life.
The choice of first-line treatment depends on clinicopathological
characteristics, such as Eastern Cooperative Oncology Group
(ECOG) performance status (PS), age, histology, comorbidity, and
molecular genetic features. In the case of the 10–15% of lung
cancers harbouring epidermal growth factor receptor (EGFR)
mutations (in the Caucasian population) and another 3–5% having
anaplastic lymphoma kinase (ALK) rearrangements, targeted
therapy with erlotinib, gefitinib, or afatinib in the former and
with crizotinib in the latter case is recommended. In the absence of
targetable mutations, platinum-based doublet chemotherapies
remain the mainstay of treatment of newly diagnosed patients
(Reck et al, 2014; Masters et al, 2015). Several doublet regimens
with third-generation agents, such as paclitaxel, gemcitabine,
docetaxel, vinorelbine, and pemetrexed have shown comparable
efficacy (Delbaldo et al, 2007). However, the benefit from these
therapies remains modest, and patients receiving pemetrexed and a
platinum derivate as first-line treatment for non-squamous NSCLC
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currently achieve a median time to progression B4–6 months and
median survival B9–15 months (Scagliotti et al, 2008; Rodrigues-
Pereira et al, 2011; Moro-Sibilot et al, 2015).
Optimisation of chemotherapy treatment would be possible
with the discovery and utilisation of reliable molecular biomarkers,
and several candidates such as expression of the excision repair
cross-complementation group 1 protein and ribonucleotide
reductase subunit M1 as biomarkers for platinum chemotherapy
(Azuma et al, 2007; Martin et al, 2008) and thymidylate synthase as
a biomarker for pemetrexed (Nicolson et al, 2013; Sun et al, 2015),
were suggested. However, insufficient tissue, problems with the
method’s reproducibility, paucity of validated biomarker trials, as
well as often discordant protein expression between primary
tumour and metastatic sites have resulted in a lack of validated
tests for cytotoxic therapy in broad clinical practice. Non-invasive
prognostic and predictive tests for standard chemotherapy regi-
mens are highly desirable.
VeriStrat (Biodesix Inc., Boulder, CO, USA) is a commercially
available blood-based proteomic mass spectrometry test developed
for assessing clinical outcome following EGFR – tyrosine kinase
inhibitor (EGFR TKI) therapy in patients with advanced NSCLC
(Taguchi et al, 2007). VeriStrat is a true multivariate test measuring
and analysing multiple components simultaneously, reflecting the
complexity of the host–tumour interactions implicated in treat-
ment outcomes. The details of the biological mechanism related to
outcomes in the VeriStrat groups are yet unknown; however, some
mass spectral features associated with the test strongly correlate
with acute-phase reactants such as serum amyloid A (Milan et al,
2012), and a large body of accumulated clinical evidence suggests
that the VeriStrat Poor classification is associated with an
aggressive disease state defined by host–tumour interactions.
Clinical utility of the test was demonstrated, across various
treatment regimens and indications, in a large number of
retrospective studies (Carbone et al, 2010; Chung et al, 2010;
Kuiper et al, 2012; Gautschi et al, 2013; Stinchcombe et al, 2013)
and confirmed in a prospective phase III study, PROSE, that has
shown the predictive role of the VeriStrat test in second-line
NSCLC patients, that is, that patients classified as VeriStrat Poor
gain significantly more benefit in terms of overall survival (OS)
when treated with chemotherapy (docetaxel or pemetrexed) rather
than erlotinib, whereas VeriStrat Good patients have similar OS in
both regimens (Gregorc et al, 2014).
In addition, the prognostic properties of the test, that is, better
outcomes associated with VeriStrat Good classification indepen-
dent of treatment, were demonstrated in the retrospective analysis
of samples from the placebo-controlled NCIC CTG BR.21 and
TOPICAL studies (Carbone et al, 2012; Lee et al, 2015). Although
being of significant clinical interest, at the time of study conception
information on the role of the test in cytotoxic chemotherapy
regimens was limited to several small data sets (Taguchi et al,
2007). To shed light on this problem, we designed a clinical trial to
evaluate the role of VeriStrat as a biomarker in first-line standard
chemotherapy for advanced NSCLC. Here we report on the
performance of the test in patients with non-squamous histology
treated with the combination of pemetrexed with cisplatin or
carboplatin.
MATERIALS AND METHODS
Eligibility criteria. Chemotherapy-naive adults (18 years or older)
with histologically or cytologically documented inoperable, locally
advanced (stage IIIB with supraclavicular lymph node metastases),
metastatic (stage IV) or recurrent NSCLC with life expectancy of
more than 3 months, ECOG PS 0–2, at least one measurable lesion
(as per response evaluation criteria in solid tumours (RECIST)
criteria version 1.1), and adequate baseline bone marrow, hepatic,
and renal functions were included in this study. Patients could
have undergone prior radiation therapy (if completed before 28
days from study enrolment), or prior surgery (if completed before
14 days from study enrolment). Exclusion criteria were prior
chemotherapy or treatment with other systemic anticancer agents,
clinically significant cardiac disease, history or evidence of
uncontrolled central nervous system disease, including brain
metastases, active, or uncontrolled systemic disease or infection,
as well as pregnancy or lactation.
All patients provided written informed consent; the trial was
carried out in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines and was approved by the Istituto
Nazionale per la Ricerca sul Cancro ethics committee. The trial was
registered at ClinicalTrials.gov (NCT02055144).
Study treatment, design, and end points. This was an observa-
tional non-randomised study with prospective sample collection.
The trial was designed to evaluate the role of VeriStrat in first-line
chemotherapy in the real-world clinical setting, where patients
were treated with platinum doublets according to the current
guidelines and practices. Patients with squamous histology were
treated with a combination of a platinum agent with gemcitabine;
patients with non-squamous NSCLC received a combination of
carboplatin (AUC 5) or cisplatin (75 mg/m2) with pemetrexed
(500 mg/m2 q 21; Carbo/Pem and Cis/Pem regimens, respectively).
The choice of platinum agent was at the physician’s discretion
based on age, ECOG PS, and creatinine clearance. Maintenance
with pemetrexed (500 mg/m2 q 21 until progressive disease or
discontinuation for toxicity) was allowed after four cycles of
combination therapy, depending on response to the induction
therapy, its toxicity, and ECOG PS. Imaging with computed
tomography scans was performed at baseline and every 6 weeks
(the equivalent of every two cycles, on schedule). Serum samples
were collected before each drug administration until patient
withdrawal and were frozen at  80 1C, until used for mass
spectrum generation for VeriStrat testing. In this paper we discuss
the results obtained from spectra collected at baseline before
commencement of treatment.
Progression-free survival (PFS) in the VeriStrat-defined
groups was chosen as the primary end point to avoid the possible
confounding effects of subsequent treatments. It was calculated
from the date of start of chemotherapy to the date of progression
or death from any cause, whichever occurred first, or to the
date of last radiological assessment in the absence of progression
or death. Secondary end points included OS and correlation of
VeriStrat classifications with best response, as well as with EGFR
or Kirsten rat sarcoma viral oncogene (KRAS) mutations and
ALK rearrangements; OS was calculated from the date of start of
chemotherapy to the date of death from any cause or to the
date of last medical contact, in absence of death. Patients
who were event-free at the last clinical assessment were censored.
The radiological response was assessed by RECIST version 1.1.
All clinical evaluations were made blinded to the VeriStrat
classification. The trial was designed and analysed in
accordance with the REMARK initiative recommendations
(McShane et al, 2005).
Spectrum acquisition and VeriStrat classification. The commer-
cially available VeriStrat test was conducted by Biodesix according
to the standard protocol described elsewhere (Taguchi et al, 2007,
Carbone et al, 2012) blinded to all clinical and treatment data. The
test utilises matrix-assisted laser desorption/ionisation time-of-
flight mass spectrometry to assign a VeriStrat Good or VeriStrat
Poor classification to a serum or plasma sample by comparison of
the intensity of eight regions in the spectra with the intensity of
those of a reference set. Each patient sample is analysed in
triplicate and VeriStrat labels are assigned if all three replicas result
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in the same classification; if they are discordant the sample is
classified as indeterminate. There were no baseline indeterminate
classifications assigned in this study.
Other biomarker measurements. Assessments of EGFR and
KRAS mutational statuses were performed with real-time PCR
Therascreen IVD (Qiagen, Germantown, MD, USA) on formalin-
fixed paraffin-embedded (FFPE) tissue. Chromosomal translocations
involving the ALK gene were assessed using fluorescence in situ
hybridisation using the Vysis dual colour Break Apart FISH Probe
kit (Abbott Molecular, Abbott Park, IL, USA) on FFPE samples.
Statistical plan and analyses. At the planning stage of the trial, we
had no data on performance of VeriStrat in advanced NSCLC
patients treated with first-line chemotherapy; however, we
expected 30% of patients to be classified as VeriStrat Poor at
baseline. The planned accrual time was 12 months, with an
additional follow-up of 12 months, with 50 patients with non-
squamous and 50 patients with squamous histology to be enroled.
Assuming a power of 0.8, and a Type I error probability associated
with testing of a null hypothesis, that the PFS of VeriStrat Poor and
VeriStrat Good groups are equal, of 0.10, we estimated the
detection limit of true hazard ratio (HR) for VeriStrat Good
subjects relative to VeriStrat Poor subjects within each histology
subtype of 0.46. The preliminary results of the trial were reported
for the pre-planned number of non-squamous patients (N¼ 55),
demonstrating significant difference in PFS between VeriStrat
Good and Poor patients overall and in the Carbo/Pem subgroup;
however, in the Cis/Pem subgroup the difference did not reach
statistical significance (Grossi et al, 2014). To confirm the
preliminary results, it was decided to increase the power of the
analysis by recruiting up to 90 patients with non-squamous
histology over extended accrual period which, allowing for an
attrition rate of 10–15% and indeterminate classification of 1–2%,
and assuming equal distributions between treatment subgroups,
would allow the detection of a HR of 0.43 in treatment subgroups
and of 0.54 overall (with the same power and type 1 error, and
accrual time increased to 36 months).
Time-to-event outcomes were analysed using data from patients
who received at least one dose of chemotherapy and were classified
as VeriStrat Good or VeriStrat Poor. Progression-free survival and
OS were described by the Kaplan–Meier method and compared by
log-rank test using GraphPad Prism 6 (La Jolla, CA, USA); the
difference between groups was also assessed with unadjusted and
adjusted Cox proportional hazard models for HRs, 95% confidence
intervals (CI), and P-values using SAS Enterprise Guide 5.1 (Cary,
NC, USA).
Patients’ clinical characteristics are presented as the median and
range for continuous variables and counts and percentages for
discrete variables. P-values for association of categorical variables
were calculated by Fisher’s exact test, using SAS Enterprise Guide
or Prism. Comparison of age between VeriStrat groups was
performed using the unpaired t-test.
RESULTS
Patient disposition and baseline characteristics. From May 2011
to October 2015, 90 patients with non-squamous histology and 15
patients with squamous histology entered the study. The accrual
period was prolonged to support the increased, according to the
updated statistical plan, number of patients eligible for platinum-
based therapy. The number of patients with squamous histology
was insufficient for analysis because of the low number of these
patients eligible for platinum doublets within the population
referred to the trial lung cancer unit, and they were not included in
the current analysis. One patient with small cell lung cancer, one
patient who withdrew consent, four patients not receiving the
study treatment, and one patient who had an excellent response
after four cycles of chemotherapy and was consequently treated
with surgery were excluded. The remaining 83 patients were
105 Patients recruited
89 Patients with non-squamous
histology
Did not receive VeriStrat classification:
Two patients did not have a baseline
sample
Four baseline samples were haemolysed
One sample failed QC
43 Patients treated with Carbo/Pem
83 Patients eligible for VeriStrat
33 Patients treated with Cis/Pem
Not eligible:
Four patients did not receive study
treatment
One patient withdrew consent
One patient had surgery after four
cycles of chemo
Excluded:
15 Patients with squamous histology
excluded from this analysis
One patient with small-cell lung cancer
excluded from the trial
Figure 1. CONSORT diagram. Abbreviations: Cis/Pem¼Cisplatin/Pemetrexed; Carbo/Pem¼Carboplatin/Pemetrexed.
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considered eligible for VeriStrat analysis. Out of those, two patients
did not provide baseline samples, four patients had haemolysed
baseline samples, and one sample failed the quality control.
Seventy-six patients received baseline VeriStrat classifications: 43
patients were treated with Carbo/Pem, 33 – with Cis/Pem; 50
(66%) patients were classified as VeriStrat Good; and 26 (34%)
were classified as VeriStrat Poor. The Consort diagram of the trial
is shown in Figure 1.
Supplementary Table 1 shows the distribution of clinical
characteristics between the treatment arms. Patients treated with
Cis/Pem were significantly younger than patients treated with
Carbo/Pem (median age: 57 years vs 70 years, t-test Po0.0001);
apart from age, patients in both treatment arms had similar clinical
characteristics.
Table 1 presents baseline characteristics of patients overall
and by VeriStrat classification. The median age of patients
was 66 years (range: 44–80 years); most patients were former or
current smokers and had ECOG PS 1. Four patients had
undergone prior radiation therapy and six had prior surgery.
All patients had stage IV disease. Only one patient had a
known ALK rearrangement, two patients had EGFR mutations
(one in exon 21 and one in exon 20; the patient with exon 20
EGFR mutation was not treated with EGFR TKI; the patient
with exon 21 EGFR mutation (L858R) received EGFR
TKI in second line), and 28 had KRAS mutations (27 in
exon 12 and 1 in exon 13); no correlations between mutation
status and VeriStrat classification were observed, although the
number of EGFR mutations and ALK rearrangements was very
small.
There was no significant association between baseline clinical
characteristics and VeriStrat classification; however, there were
more patients receiving maintenance therapy in the VeriStrat Good
group than in the VeriStrat Poor group (P¼ 0.0065).
Outcome Measures and the Role of VeriStrat
PFS and OS. By the time of the database lock, 68 patients (89%)
experienced PFS events (43 in the VeriStrat Good and 25 in the
VeriStrat Poor groups) and 55 patients (72%) had died (33 and 22
in VeriStrat Good and Poor groups, respectively). In the overall
population, the median PFS was 3.8 months (95% CI 2.7–5.7),
whereas the median OS was 7.9 month (95% CI 5.7–10.8); the
median follow-up time was 26.2 months.
Both PFS and OS were significantly longer in patients classified
as VeriStrat Good, as illustrated by the Kaplan–Meier curves
(Figure 2A and B). The median PFS in the VeriStrat Good patients
vs VeriStrat Poor patients was 6.5 vs 1.6 months (HR¼ 0.36, 95%
CI 0.22–0.61, Po0.0001); the median OS was 10.8 months vs 3.4
months (HR¼ 0.26, 95% CI 0.15–0.47, Po0.0001), see Table 2.
VeriStrat was prognostic in the multivariate analysis adjusted for
clinical characteristics with P¼ 0.0002 and o0.0001 for PFS and
OS, respectively (Table 3A). When treatment regimen and
maintenance status were added to the Cox proportional hazard
model, VeriStrat remained significant (P¼ 0.0019 for PFS and
Po0.0001 for OS; Table 3B), indicating that the observed
differences between VeriStrat Good and Poor patients are not just
due to differences in maintenance or treatment regimen between
these two groups.
These findings remained consistent in the exploratory subgroup
analysis by treatment regimen: VeriStrat Good patients had a
statistically significant advantage over VeriStrat Poor in PFS and
OS both in Carbo/Pem and Cis/Pem subgroups (Figure 2C and D
and Table 2). In the Carbo/Pem subgroup, the median PFS
was 3.8 and 1.6 months in VeriStrat Good and VeriStrat Poor,
respectively (HR¼ 0.30, 95% CI 0.14–0.62, P¼ 0.0007), whereas
the median OS was 9.4 and 3.4 months, respectively (HR¼ 0.26
95% CI 0.12–0.54, P¼ 0.0002); in the Cis/Pem subgroup, the
median PFS was 7.9 months in the VeriStrat Good group and 1.7
months in the VeriStrat Poor group (HR¼ 0.39, 95% CI 0.18–0.85,
P¼ 0.0141), whereas the median OS was 17.7 and 4.2 months,
respectively (HR¼ 0.25, 95% CI 0.10–0.62, P¼ 0.0013). Numerical
differences between the median PFS and OS by treatment regimen
within VeriStrat classification groups reflect the better overall
outcomes observed in the Cis/Pem arm vs the Carbo/Pem arm
(Table 2 and Supplementary Figure 1A and B), which may be
explained by the younger age of patients in the Cis/Pem subgroup
and other factors influencing the choice of chemotherapy in this
non-randomised trial.










Range 44–80 44–76 46–80 0.2639
Median 66 66 66
Gender
Male, N (%) 51 (67) 34 (68) 17 (65) 1
Female, N (%) 25 (33) 16 (32) 9 (35)
Histology
Adenocarcinoma, N (%) 75 (99) 49 (98) 26 (100) 1
NOS, N (%) 1 (1) 1 (2) 0
Stage
IV 76 (100) 50 (100) 26 (100) —
Smoking
Never smoker, N (%) 7 (9) 4 (8) 3 (11) 0.8219
Former smoker, N (%) 30 (40) 21 (42) 9 (35)
Smoker, N (%) 39 (51) 25 (50) 14 (54)
Prior radiation therapy
No, N (%) 72 (95) 48 (96) 24 (92) 0.6028
Yes, N (%) 4 (5) 2 (4) 2 (8)
Prior surgery
No, N (%) 70 (92) 45 (90) 25 (96) 0.6576
Yes, N (%) 6 (8) 5 (10) 1 (4)
Maintenance
No, N (%) 44 (58) 23 (48) 21 (81) 0.0065
Yes, N (%) 32 (42) 27 (52) 5 (19)
ECOG PS
0, N (%) 20 (26) 15 (30.00) 5 (19) 0.4144
1, N (%) 54 (71) 33 (66.00) 21 (81)
2, N (%) 2 (3) 2 (4.00) 0
Chemotherapy type
Carbo/Pem, N (%) 43 (57) 28 (56.00) 15 (58) 1
Cis/Pem, N (%) 33 (43) 22 (44.00) 11 (42)
KRAS status
Wild type, N (%) 31 (41) 24 (48.00) 7 (27) 0.1766
Mutation, N (%) 29 (38) 16 (32.00) 13 (50)
Unknown, N (%) 16 (21) 10 (20.00) 6 (23)
EGFR status
Wild type, N (%) 67 (88) 43 (86.00) 24 (92) 0.855
Mutant, N (%) 2 (3) 2 (4.00) 0
Unknown, N (%) 7 (9) 5 (10.00) 2 (8)
ALK translocation
Negative, N (%) 54 (71) 37 (74.00) 17 (65) 0.6193
Positive, N (%) 1 (1) 1 (2.00) 0
Unknown, N (%) 21 (28) 12 (24.00) 9 (35)
Abbreviations: ALK¼ anaplastic lymphoma kinase; Carbo¼ carboplatin; Cis¼ cisplatin;
ECOG¼Eastern Cooperative Oncology Group; EFGR¼epidermal growth factor
receptor; KRAS¼Kirsten rat sarcoma viral oncogene; NOS¼not otherwise specified;
Pem¼pemetrexed; PS¼performance status.
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Response. Objective response rate was higher in the VeriStrat
Good group (P¼ 0.0032). In fact, 31% of VeriStrat Good patients
achieved an objective response (1 complete and 14 partial),
whereas there were no responses in the VeriStrat Poor group; 27
and 7 VeriStrat Good patients had stable disease and disease
progression, respectively; in the VeriStrat Poor group there
were 13 patients with stable disease and 9 patients with
progressive disease. One VeriStrat Good patient and four
VeriStrat Poor patients died before the first radiological
assessment (see Table 4).
DISCUSSION
The advent of the third generation of cytotoxic agents led to some
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Figure 2. Kaplan–Meier curves of PFS and OS. (A) Progression-free survival by VeriStrat in overall population. (B) Overall survival by VeriStrat in
overall population. (C) Progression-free survival by VeriStrat in treatment subgroups. (D) Overall survival by VeriStrat in treatment subgroups.
Abbreviations: VSG¼VeriStrat Good; VSP¼VeriStrat Poor.




month HR (95% CI) Log-rank P
Median (95% CI),
month HR (95% CI) Log-rank P
VSG 6.5 (3.9–8.8) 0.36a (0.22–0.61) o0.0001 10.8 (7.8–17.7) 0.26a (0.15–0.47) o0.0001
VSP 1.6 (1.1–2.5) 3.4 (2.4–4.3)
VSG Carbo/Pem 3.8 (2.7–8.7) 0.30a (0.14–0.62) 0.0007 9.4 (5.0–15.3) 0.26a (0.12–0.55) 0.0002
VSP Carbo/Pem 1.6 (1.0–2.5) 3.4 (1.0–4.3)
VSG Cis/Pem 7.9 (5.2–13.1) 0.39a (0.18–0.85) 0.0141 17.7 (9.9–24.9) 0.25a (0.10–0.62) 0.0013
VSP Cis/Pem 1.7 (1.1–3.9) 4.2 (2.6–8.9)
Carbo/Pem 2.8 (2.0–4.0) 1.59b (0.97–2.61) 0.0627 6.0 (4.2–10.0) 1.64b (0.96–2.82) 0.0701
Cis/Pem 5.7 (3.8–8.8) 10.3 (6.6–17.9)
Abbreviations: CI¼ confidence interval; Carbo¼ carboplatin; Cis¼ cisplatin; HR¼ hazard ratio; N/R¼not reached; OS¼overall survival; Pem¼pemetrexed; PFS¼progression-free survival;
VSG¼VeriStrat Good; VSP¼VeriStrat Poor.
aHR calculated for VeriStrat Good vs VeriStrat Poor using unadjusted Cox proportional hazard model.
bHR calculated for Carbo/Pem vs Cis/Pem using unadjusted Cox proportional hazard model.
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however, the prognosis for these patients is still dire, the choice of
an optimal treatment strategy remains challenging, and relevant
biomarkers are needed, especially when targetable oncogenic
drivers, such as EGFR or ALK, are missing. The most notable
progress achieved in treatment of advanced NSCLC in the last
years is associated with immunotherapy, in particular with
development and approval by the Food and Drug Administration
of the immune checkpoint inhibitors for previously treated
advanced NSCLC patients. However, in the first line not all
patients achieve greater clinical benefit from immunotherapies
compared with platinum doublets, as the recent failure of the
Checkmate 026 trial to show the advantage of nivolumab vs
platinum-based chemotherapy in terms of PFS, has demonstrated






08/5/2016). Although it is possible that immunotherapy will be
used in some NSCLC patients (West, 2014), it is most likely that
traditional chemotherapy still remains a viable option for many
patients with advanced disease. Currently, none of the studied
biomarkers for cytotoxic therapy is employed in broad clinical
practice for reasons ranging from insufficient clinical validation, to
large variations in evaluation procedures and heterogeneity of the
tumours, to the principal limitations of single-molecule measure-
ments as biomarkers of complex biological processes (Malottki
et al, 2016; Souglakos, 2015; Toffart et al, 2014).
VeriStrat, being a multivariate blood-based proteomic test that
relates to the state of the whole organism, is better suited to
overcome the limitations of single-molecule measurements to
reflect complex biological processes of tumour–treatment-and–
host interactions. The test is highly reproducible, provides rapid
results from a non-invasive blood draw, and has been validated in
multiple studies, including a prospective randomised phase III trial
PROSE (Gregorc et al, 2014). It is commercially available and can
be rapidly adopted in new indications.
Forty per cent of patients with newly diagnosed NSCLC have
stage IV disease, and B70% of these patients are affected by non-
squamous histology. The cohort analysed in this study is
representative of this clinically important population of patients
able to receive platinum-based chemotherapy: non-squamous
NSCLC, ECOG PS 0–1, stage IV; 5% of patients had prior
radiation, 8% had surgery, all of them treated with a combination
of a platinum agent and pemetrexed with 42% continuing on
maintenance therapy with pemetrexed after first line. The small
number of enroled patients with ECOG PS 2 reflects the relatively
low proportion of these patients in our practice deemed fit for a
platinum-based regimen.
In this study, the choice between platinum agents was based on
creatinine levels, age, and other clinical characteristics. Patients
treated with Cis/Pem were younger, which reflects the common
practice of prescribing cisplatin to fitter patients, and had longer
PFS and OS than patients treated with Carbo/Pem, in agreement
with previously published data (Ardizzoni et al, 2007; Moro-Sibilot
et al, 2015), although the difference did not reach statistical
significance. VeriStrat was able to identify patients who were more
or less likely to have good outcomes from the platinum doublet in
terms of PFS and OS in the overall population, as well as separately
in the Carbo/Pem and Cis/Pem subgroups. Also notable is the
absence of objective responses in patients classified as VeriStrat
Poor, whereas 31% of VeriStrat Good patients had either complete
or partial responses. In addition, as patients classified as VeriStrat
Good were more likely to benefit from first-line chemotherapy in
terms of survival and response, they were also more likely to
receive maintenance with pemetrexed as single agent compared
with those patients classified as VeriStrat Poor.
These results support our findings from the retrospective
analysis of a similar cohort of patients with non-squamous NSCLC
treated with a combination of cisplatin and gemcitabine in first line
in the NExUS study, where VeriStrat Good classification was also
associated with better prognosis, as well as with previously
published data in the second line of treatment with erlotinib or
chemotherapy from the PROSE trial (Gregorc et al, 2014) and
erlotinib and placebo arms of the BR 21 study (Carbone et al, 2012)
Interestingly, in the second arm of the NExUS study VeriStrat Poor
patients treated with sorafenib in addition to platinum doublet had
Table 3. Adjusted Cox proportional hazard analysis of PFS and OS
PFS OS
HR (95% CI) P-value HR (95% CI) P-value
Model including only clinical characteristics
VeriStrat classification (good vs poor) 0.32 (0.18–0.58) 0.0002 0.23 (0.12–0.44) o0.0001
Gender (male vs female) 1.27 (0.72–2.24) 0.4028 1.58 (0.84–2.98) 0.1604
Smoking status (ever vs never) 1.09 (0.46–2.60) 0.8519 1.49 (0.58–3.81) 0.4062
ECOG PS (X1 vs 0) 1.10 (0.62–2.01) 0.7213 1.07 (0.54–2.12) 0.8414
KRAS status (mutant vs WT or unknown) 0.98 (0.54–1.80) 0.9505 1.21 (0.62–2.34) 0.5794
KRAS known (known vs unknown) 3.13 (1.41–6.95) 0.0049 2.87 (1.17–7.07) 0.0219
Model including clinical characteristics and treatment
VeriStrat classification (good vs poor) 0.39 (0.22–0.71) 0.0019 0.23 (0.11–0.46) o0.0001
Gender (male vs female) 1.36 (0.77–2.39) 0.2933 1.68 (0.87–3.23) 0.1220
Tx regimen (Cis/Pem vs Carbo/Pem) 1.87 (1.10–3.16) 0.0202 1.86 (1.05–3.32) 0.0343
Smoking status (ever vs never) 1.43 (0.58–3.56) 0.4396 2.73 (0.91–8.20) 0.0727
ECOG PS (X1 vs 0) 1.12 (0.61–2.03) 0.7204 1.00 (0.51–1.99) 0.9976
KRAS status (mutant vs WT or unknown) 1.11 (0.61–2.04) 0.7312 1.26 (0.64–2.47) 0.5032
KRAS (known vs unknown) 2.31 (1.06–5.07) 0.0363 1.90 (0.78–4.61) 0.1553
Maintenance (yes vs no) 0.35 (0.20–0.60) 0.0002 0.27 (0.14–0.52) o0.0001
Abbreviations: CI¼ confidence interval; Carbo¼ carboplatin; Cis¼ cisplatin; ECOG¼Eastern Cooperative Oncology Group; HR¼ hazard ratio; KRAS¼Kirsten rat sarcoma viral oncogene;
OS¼overall survival; Pem¼pemetrexed; PFS¼progression-free survival; PS¼performance status; Tx¼ treatment; WT¼wild type.
Table 4. Objective response by VeriStrat status
VeriStrat Good VeriStrat Poor P-value
PR/CR 1/14 (30.6%) 0 (0)
0.0032
PD/SD 7/27 (69.4%) 9/13 (100%)
ED 1 4
Abbreviations: CR¼ complete response; ED¼ early death; PD¼progressive disease;
PR¼partial response; SD¼ stable disease.
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similar PFS to patients classified as VeriStrat Good (Vansteenkiste
et al, 2012). Furthermore, when the role of VeriStrat was explored
in patients treated with single agent gemcitabine, no significant
difference between VeriStrat Good and Poor survival curves was
found (Stinchcombe et al, 2013). These data, in combination with
the results of the current study, suggest that the test may be
predictive of differential outcomes between cytotoxic therapies.
However, the limitation of this study is that in the absence of a
control arm we could only show the prognostic effect of the test,
that is, that patients classified as VeriStrat Good have better
outcomes than those classified as VeriStrat Poor, and could not
assess the predictive power with respect to differential benefit from
some alternative treatment. A two-arm trial, which could extend
the evidence of the predictive power of the test to the first-line
setting and point to a better therapeutic option for VeriStrat Poor
patients, is warranted. Nevertheless, facilitating patient under-
standing of the prognosis, independent of therapy, is critical for
making informed decisions regarding treatment and end-of-life
care (Enzinger et al, 2015).
In conclusion, this study met its objectives and demonstrated
the clinical utility of VeriStrat as a prognostic marker in
chemotherapy-naive patients with non-squamous NSCLC treated
with standard chemotherapy regimens. In the era of genomic
testing the utility of VeriStrat is in providing information
complementary to that gained by an orthogonal methodology.
The test can be useful for oncologists for planning the treatment
strategy. Whereas patients with the VeriStrat Good classification
have a better prognosis when treated with platinum doublets,
classification as VeriStrat Poor may be an indication that
alternative therapeutic options, including participation in clinical
trials, should be explored. In addition, the results of the test may
support an informed patient–physician discussion of the disease
prognosis.
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